Epilepsy Brain tumors Overweight
Conditions
Interventions
Group 1: 20 brain tumor patients (glucose-avid brain lesions: 5 with cerebral metastases, 5 with lymphomas, 10 high-grade gliomas according to the updated WHO classification 2021) with a Karnofsky per
Sponsors
Medizinische Universität Wien
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Brain tumor patients: (glucose-avid brain lesions: 5 with cerebral metastases, 5 with lymphomas, 10 high-grade gliomas according to the updated WHO classification 2021) with a Karnofsky performance status =70% who received a routine MRI protocol at 3 T including contrast medium -enhancing agents within two weeks prior to the first study-related measurement but before any biopsy, resection, or radiosurgery occurred. For this pilot study, the group of patients with brain metastases will include distant metastases of all types of primary tumors) Epilepsy patients: (Clearly defined epileptogenic lesions in MRI such as malformations of cortical development, vascular malformations, scars, etc., routine clinical examinations including long-term video EEG monitoring, FDG-PET, routine clinical T1/T2-weighted MRI) Lean control group: (healthy lean adults, age = 18 years, body mass index 18.5–24.9, written informed consent) Overweight control and intervention group: (adults with overweight , age = 18 years, body mass index = 28, “common” overweight without overt type 2 diabetes, written informed consent, no dietary intervention)
Exclusion criteria
Exclusion criteria: MRI inclusion and exclusion criteria: - Exclusion of pregnancy - Exclusion of nursing mothers - Anamnestic exclusion of a metal implantation (pacemaker, metal heart valves, surgical clips, implanted electronic infusion pumps, tattoos and the like). - Exclusion of a contrast medium allergy - Anamnestic exclusion of claustrophobia - Exclude recent head/brain surgery - Exclusion of a metabolic disorder (HbA1c>6%) (pathological findings on magnetic resonance imaging; any known history of neurological, metabolic, cardiovascular, or severe psychological disorders; type 2 diabetes mellitus; monogenetic or syndromal forms of obesity; endocrine causes of obesity, e.g. Cushing’s syndrome, hypothyroidism, or other significant endocrine disorders; high physical activity, i.e. more than 5 sessions of moderate- to high-intensity sport per week; drug abuse or alcohol consumption > 15 drinks/week; use of antidepressants, neuroleptics, or other current drug treatment; contraindications for 7 Tesla magnetic resonance imaging, including claustrophobia, fresh tattoos, metal implants, or pacemakers; pregnancy or breastfeeding)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is possible to detect metabolic changes in glucose/neurotransmitter metabolism in selected brain pathologies (e.g. brain tumors, epilepsy) with expected metabolic changes. The study aims to determine whether a four-week low-calorie diet in individuals with overweight induces measurable changes in brain glucose and neurotransmitter metabolism, systemic glucose dynamics, and body weight. | — |
Secondary
| Measure | Time frame |
|---|---|
| Non-invasive imaging of glucose and neurotransmitter metabolism via time-resolved MRSI is possible using both clinical routine 3T and experimental 7T MR scanners. The study aims to determine whether a four-week low-calorie diet induces measurable changes in food craving and diet-related decision-making processes. | — |
Countries
Austria
Contacts
Public ContactWolfgang Bogner
Medizinische Universität Wien
Outcome results
None listed